Özkan ALAN, Atakan DEMİR

Rektum Kanserinin Prognozunu Öngermede Ortalama Trombosit Hacmi (MPV)'nin Rolü

Amaç:Rektum kanseri kolorektal kanserlerin alt tipidir. Etyopatogenezi kolon kanserlerine benzemekle birlikte, tedavi yaklaşımında farklılıklar vardır. Literatürde ortalama trombosit volümü (MPV) ile gastrointestinal kanser hastalarındaki inflamasyonla ilişki gösterilmiştir. Bu nedenle çalışmamızda neoadjuvan tedavi alan rezeke rektum kanseri hastalarının prognozunu belirlemede MPV değerinin rolünü değerlendirmeyi amaçladık. Materyal ve Metot:2011-2018 yılları arasında neoadjuvan kemoradyoterapi almış opere 80 rektum adenokarsinom tanılı hastanın verileri retrospektif olarak değerlendirildi. MPV ‘nin hastalıksız sağ kalım için prognostik önemi araştırıldı. Bulgular:Hastaların 55'i (%69) erkekti. Medyan yaş 56 (minimum 22-maksimum 83) idi. En sık görülen histopatolojik tip adenokarsinomdu(94%). MPV için ideal kestirim değeri 7,65 saptandı [AUC:0.74 (0.63-0.85) / p

MEAN PLATELET VOLUME (MPV) FOR PREDICTING PROGNOSIS OF RECTUM CANCER AFTER NEOADJUVANT TREATMENT

Aim:Rectum cancer is a subtype of colorectal cancer. Its etiology and etiopathogenesis is similar to colon cancer. However, it is differentiated from colon tumors because of its anatomic location and treatment approach. In the literature, Mean Platelet Volume (MPV) has been shown to correlate with inflammation in gastrointestinal cancer patients. Based on this fact, we aimed to evaluate the MPV value for predicting prognosis of rectum cancer patients who are treated with neoadjuvant chemoradiotherapy.Materials and Methods:We retrospectively collected the data of80 operated rectum adenocarcinoma patients who were treated neoadjuvant chemoradiotherapy between 2011 and 2018. MPV value was investigated as prognostic factors for disease free survival.Results:Fifty-five patients were male (69%). Median age was 56 (range 22 to 83 years). The most common histopathologic was adenocarcinoma (94%). The ideal cut-off value of pretreatment MPV that predicted disease-free survival was 7.65 in the ROC analysis [AUC:0.74 (0.63-0.85); p

PDF

___

1. Ross M., Romrell L., Kaye G.I., “Histology: A Text and Atlas”, 3rd Edition, William&Wilkins.1995; 490 –4.
2. Sadler T.W. “Medical Embryology’, 6th Edition, Williams&Wilkins. 1990;237-58.
3. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124.
4. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620.
5. Glimelius B, Cavalli-Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach—present status. Scand JGastroenterol.2012;47:296–314.
6. Sandler RS. Epidemiology and risk factors for colorectal cancer. Gastroenteol Clin North Am. 1996;25(4):717-35.
7. Burt RW. Familial risk and colorectal cancer. Gastroenteol Clin North Am.1996;25(4):793-805.
8. Pietra N, Sarli L, Sansebastiano G. Prognostic value of ploidy, cell proliferation cinetics and convantionals clinicopathologic criteria in patients with colorectal carcinoma. A prospective study. Dis Colon Rectum. 1996; 39:494-503.
9. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996; 7(2):157-61.
10. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des. 2011;17(1):47-58.
11. Bancroft AJ, Abel W, et al. Mean trombosit volume is a useful parameter: a reproducible routine method using a modified Coulter Thrombocytometer.Trombosits 2000;11: 379-87.
12. S.R.Jackson, J.M.Carter. Platelet volume: Laboratory measurement and clinical application. Blood Reviews.1993;7(2):104-113.
13. Senaran H, Ileri M, Altinbaş A, Koşar A, Yetkin E, Oztürk M, et al.Thrombopoietin and mean trombosit volüme in coronary artery disease. Clin Cardiol. 2001;24(5):405-8.
14. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012;9(07):e1001275.
15. Rickles F R, Levine M N. Epidemiology of thrombosis in cancer. Acta Haematol.2001;106(1-2):6-12.
16. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996;9(9):1826-30.
17. Karagöz B, Sücüllü İ, Sayan Ö, Bilgi O,Tuncel T,Filiz Aİ,et al. Platelet indices in patients with colorectal cancer. Cent Eur J Med.2010;5(3):365-8.
18. Kandemir EG, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M. Prognostic significance of thrombocytosis in node negative colon cancer. J Int Med Res. 2005;33(2):228- 35.
19. Aksoy S, Kilickap S, Hayran M, Harputluoglu H, Koca E, Dede DS, et al. Platelet size has diagnostic predicive value, for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol. 2008;30:214-9.
20. Matowicka-Karna J, Kamocki Z, Polińska B, Osada J, Kemona H. Platelets and Inflammatory Markers in Patients with Gastric Cancer. Clinical Dev Immunol. 2013;2013: 401623.
21. Baldane S, Ipekci SH, Sozen M, and Kebapcilar L. Mean Platelet Volume Could be a Possible Biomarker for Papillary Thyroid Carcinomas. Asian Pac J Cancer Prev. 2015;16 (7):2671-4.
22. Oge T, Yalcin OT, Ozalp SS, Isikci T. Platelet volume as a parameter for platelet activation in patients with endometrial cancer. J Obstet Gynaecol. 2013; 33(3): 301–4.
23. Polinska B, Matowicka-Karna J, Kemona H. Assessment of the influence of the inflammatory process on the activation of blood platelets and morphological parameters in patients with ulcerative colitis (colitis ulcerosa). Folia Histochem Cytobiol. 2011;49(1):119-24.
24. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE et al. Mean platelet volume: A useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001;96(3):776-81.
25. Yuksel O, Helvaci K, Basar O, Koklu S, Caner S, Helvaci N et al. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets. 2009;20(4):277-81.
26. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75(3):291- 4.
27. Aktas G, Sit M, Tekce H, Alcelik A, Savli H, Simsek T, et al. Mean platelet volume in nasal polyps. The West Indian Medical Journal.2013;62(6):515-8.
28. Pattraporn Tajarernmuang, Arintaya Phrommintikul, Atikun Limsukon, Chaicharn Pothirat, and Kaweesak Chittawatanarat, “The Role of Mean Platelet Volume as a Predictor of Mortality in Critically Ill Patients: A Systematic Review and Meta-Analysis,” Critical Care Research and Practice, vol. 2016, Article ID 4370834, 8 pages,2016.
29. Koksal D, Segmen F, Koyuncu A, Atasever M and Berkoglu M. Mean platelet volume: is there a link between stage and venous Thrombosis in non-small cell lung cancer. Solunum Hastalıkları. 2013;24(2):53- 57.
30. Yun Z, ZhangX,Liu Y, Liu T, Liu Z, Wang R and Yu K. Lower mean platelet volume predicts poor prognosis in renal cell carcinoma. Scientific Reports. 2017; 7(1):6700.
31. Shen,XM,Xia YY, Lian L, Zhou C, Li XL, Han SG, Zheng Y, Gong FR, Tao M, Mao ZQ and and Li W. Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer. Oncol Lett. 2016;12(4):2501–6
32. Tuncel T, Ozgun A, Emirzeoglu L, Celik S, Bilgi O, Karagoz B. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with Bevacuzimab combined chemotherapy. Asian Pac J Cancer Prev.2014;15(15);6421-3.
33. Li ZY, Li Y, Jiang Z, Wang RT and Wang XS. Elevated mean platelet volume is Associated with presence volume is associated with presence of Colon Cancer. Asian Pac J Cancer Prev.2014;15(23):10501-4
34. Ferroni P, Guadagni F, Riondino S, Portarena I, Mariotti S, La Farina F, Davì G, Roselli M. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica.2014;99(10):1638-44.
35. Wlodarczyk M, Kasprzyk J, Sobolewska Wlodarczyk A, Wlodarczyk J, Tch'orzweski M, Dziki A and Dziki L. Mean platelet volume as a possible biomarker of tumor progression in rectal cancer. Cancer Biomarkers. 2016;17(4):411-7.
36. Vizioli L, Muscari S, Muscari A.The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509-15.
37. Celik T,Yuksel UC,Iyisoy A,Kursakioglu H,OzcanO ,Kilic S ,et al Effects of nebivolol on platelet activation in hypertensive patients ; a comparative study with metoprolol. Int J Cardiol.116:206-11,
38. Demirtunc R, Duman D, Basar M. Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. Clin Drug Investig. 2007;27(6):435-41.